BUDGET IMPACT ANALYSIS OF CEFTAROLINE VS. LINEZOLID OR VANCOMYCIN ON THE TOP OF STANDARD THERAPY IN THE TREATMENT OF COMPLICATED SKIN AND SOFT TISSUES INFECTIONS IN RUSSIAN FEDERATION

Author(s)

Kulikov A*, Komarov I I.M. Sechenov First Moscow State Medical University, Moscow, Russia

OBJECTIVES: To estimate the budget impact of the inclusion of ceftaroline compared to linezolid or vancomycin on the top of complicated skin and soft tissues infections treatment scheme with antimicrobials according to Russian healthcare system. METHODS: The budget impact analysis was conducted. Direct expenses associated with complicated skin and soft tissues infections and resulting follow-up costs were calculated using general tariff agreement of Russian obligatory insurance system and official national statistics. For reference, accepted exchange rate was 1 EUR = 40 RUB. RESULTS: Ceftaroline inclusion into the standard complicated skin and soft tissues infections therapy provided cost saving benefits compared with inclusion of linezolid or vancomycin in the complicated skin and soft tissues infections standard therapy scheme. Total healthcare costs of complicated skin and soft tissues infections therapy were approximately 77 997 RUB (1 950 EUR) per patient in ceftaroline group (therapy duration – 9 days), 78 816 RUB (1 970 EUR) per patient in vancomycin group (therapy duration – 10 days) and 117 893 RUB (2 947 EUR) per patient in linezolid group (therapy duration – 12 days). Treatment of complicated skin and soft tissues infections using standard therapy with ceftaroline inclusion compared to one with vancomycin or linezolid leads to cost savings of 819 RUB (20 EUR) or 39 896 RUB (997 EUR) per patient, respectively. CONCLUSIONS: The results of budget impact analysis illustrate that including ceftaroline into the standard therapy of complicated skin and soft tissues infections in comparison with vancomycin or linezolid has potential to reduce Russian healthcare system total costs for complicated skin and soft tissues infections treatment.

Conference/Value in Health Info

2013-11, ISPOR Europe 2013, The Convention Centre Dublin

Value in Health, Vol. 16, No. 7 (November 2013)

Code

PIN24

Topic

Economic Evaluation

Topic Subcategory

Budget Impact Analysis

Disease

Infectious Disease (non-vaccine), Sensory System Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×